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Overwhelming evidence supports the importance of the sympathetic nervous system in heart failure. In
contrast, much less is known about the role of failing cholinergic neurotransmission in cardiac disease. By
using a unique genetically modified mouse line with reduced expression of the vesicular acetylcholine transporter (VAChT) and consequently decreased release of acetylcholine, we investigated the consequences of
altered cholinergic tone for cardiac function. M-mode echocardiography, hemodynamic experiments, analysis
of isolated perfused hearts, and measurements of cardiomyocyte contraction indicated that VAChT mutant
mice have decreased left ventricle function associated with altered calcium handling. Gene expression was
analyzed by quantitative reverse transcriptase PCR and Western blotting, and the results indicated that
VAChT mutant mice have profound cardiac remodeling and reactivation of the fetal gene program. This
phenotype was attributable to reduced cholinergic tone, since administration of the cholinesterase inhibitor
pyridostigmine for 2 weeks reversed the cardiac phenotype in mutant mice. Our findings provide direct
evidence that decreased cholinergic neurotransmission and underlying autonomic imbalance cause plastic
alterations that contribute to heart dysfunction.
function, such as heart failure (15), diabetes (29), and hypertension (13, 50). Moreover, excessive adrenergic activation in association with diminished parasympathetic activity is detrimental in
cases of heart failure (35). Recent studies demonstrated that
M2-AChR knockout (KO) mice exhibit impaired ventricular
function and increased susceptibility to cardiac stress, suggesting
a protective role of the parasympathetic nervous system in the
heart (26). In support of this hypothesis, vagal stimulation has
been shown to be of benefit in cases of heart failure (28). While
most of these studies focus on possible protective actions of vagal
activity and their relation to arrhythmogenesis, the mechanisms
associated with the regulation of ventricular contractility by cholinergic neurotransmission are still unclear.
ACh-mediated signaling plays important roles in maintaining synaptic connections during development (5, 9, 32); hence,
chronic disturbance of cholinergic tone, as observed in cases of
dysautonomia, could contribute to altered myocardial function. Rich cholinergic innervations are found in the sinoatrial
node (SAN), the atrial myocardium, the atrioventricular node,
and the ventricular conducting system in many species (24).

The role of sustained cholinergic tone in long-term cardiac
function is poorly understood. Cardiac regulation by the parasympathetic nervous system is mediated primarily by acetylcholine
(ACh) binding to the M2 muscarinic ACh receptor (M2-AChR)
(12). In addition, cholinergic tone also controls sympathetic activity, as preganglionic neurotransmission is cholinergic in the two
branches of the autonomic nervous system. Reduced parasympathetic function occurs during aging (11) and has been observed
for patients with several disorders that ultimately affect cardiac
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MATERIALS AND METHODS
Animal models and drug administration. VAChT mutant mice (VAChT
KDHOM) were described previously (41). VAChT mutant mice were generated by
targeting the 5⬘ untranslated region of the VAChT gene by homologous recombination in a mixed 129S6/SvEvTac ⫻ C57BL/6J background and were backcrossed to C57BL/6Uni (from the University of Campinas) for 3 generations
(N3), as further backcrossing into the C57BL/6 background caused infertility
(data not shown). Heterozygous mice were intercrossed to generate the VAChT
mutant and wild-type controls used in these experiments. Wild-type and mutant
mice 1, 3, or 6 months old were used in this study for evaluation of cardiac
function and myocyte Ca2⫹ transients. Pyridostigmine (PYR; Sigma) administration to mice was performed twice daily by intraperitoneal injection for two
weeks (1 mg/kg body weight).
VAChT-null mice (VAChTdel/del), in which the VAChT open reading frame
(ORF) was deleted by using Cre/loxP, were described previously (9). VAChTdel/del
mice die shortly after birth due to respiratory failure; therefore, experiments were
performed with embryonic day 18.5 (E18.5) embryos. VAChTwt/del mice were intercrossed to generate the VAChT-null mice.
Animals were housed in groups of three to five per cage in a temperaturecontrolled room with 12-h/12-h light/dark cycles in microisolator cages. Food and
water were provided ad libitum.
Animals were maintained at the Federal University of Minas Gerais (UFMG),
Brazil, and at the University of Western Ontario in accordance with NIH guidelines for the care and use of animals. Experiments were performed according to
approved animal protocols from the Institutional Animal Care and Use Committee at the UFMG and at the University of Western Ontario.
Hemodynamic measurements. Invasive left ventricle (LV) hemodynamic measurements were made using a Millar Mikro-tip pressure transducer (Millar Instruments, Houston, TX) as previously described (20, 33, 51). LV parameters,
according to the blood pressure module in Chart analysis software (PowerLab;
AD Instruments), were obtained at the baseline and following the administration

of isoproterenol (ISO; 0.02 g or 0.5 g intraperitoneally [i.p.]) as previously
described for anesthetized mice (17).
M-mode echocardiography. Cardiac function under noninvasive conditions
was assessed by two-dimensional guided M-mode echocardiography of halothane-anesthetized mice as previously described (2). Heart rates (HRs) recorded
under this condition were 541.5 ⫾ 21.4 beats per min (bpm) for the wild-type
(WT) mice (8 mice), 520.2 ⫾ 25.2 bpm for the VAChT KDHOM mice (5 mice),
and 549.0 ⫾ 23.4 bpm for the VAChT KDHOM mice with PYR (5 mice).
Electrocardiography. A dorsally mounted radio frequency transmitter and
wire leads (lead II configuration) were implanted subcutaneously under anesthesia. Chronic electrocardiogram (ECG) recordings from conscious mice were
acquired with the Data Sciences International telemetry system (Transoma Medical, St. Paul, MN) as previously described (33). ECG recordings were initiated
following a minimum of 7 days postimplantation. HR and HR variability (HRV)
parameters were obtained and analyzed under basal (saline), atropine (1 mg/kg,
i.p.), propranolol (1 mg/kg, i.p.), or atropine-plus-propranolol conditions by
using the Dataquest A.R.T. software (Transoma Medical). The analysis for both
HR and HRV was performed 15 min following administration of drugs.
Cardiomyocyte isolation and Ca2ⴙ recordings. Adult ventricular myocytes were
freshly isolated and stored in Dulbecco’s modified Eagle’s medium (DMEM; Sigma)
until they were used (within 6 h) as previously described (21). Intracellular Ca2⫹
imaging experiments were performed with Fluo-4 AM (10 M; Invitrogen, Eugene,
OR)-loaded cardiomyocytes for 25 min, and these were subsequently washed with an
extracellular solution that contained 1.8 mmol/liter Ca2⫹ to remove the excess dye.
Cells were electrically stimulated at 1 Hz to produce steady-state conditions. The
confocal line-scan imaging was performed with a Zeiss LSM 510META confocal
microscope. The amplitude of the Ca2⫹ transient evoked by the application of a
Ca2⫹- and Na⫹-free solution containing 10 mM caffeine was used as an indicator of
the SR Ca2⫹ load (36). Cells were subjected to a series of preconditioning pulses (1
Hz) before caffeine was applied. Ca2⫹ spark frequencies in resting ventricular myocytes were recorded. Digital image processing was performed by using customdevised routines created with the IDL programming language (Research Systems,
Boulder, CO). The Ca2⫹ level was reported as F/F0 (or as ⌬F/F0), where F0 is the
resting Ca2⫹ fluorescence.
Langendorff preparation-perfused hearts. Briefly, once removed from the
animal, the heart was perfused with a Krebs-Ringer solution, which was delivered
at 37°C with continuous gassing with 5% CO2 to yield a physiological pH of 7.4.
Hearts were perfused with this solution for 50 min as previously described for
mice and rats (6, 14).
Histological assessment of cardiac fibrosis. In both WT and VAChT KDHOM
groups, the fibrotic area in the LV and interventricular septum (IS) was evaluated by Masson’s trichrome staining. Whole hearts were harvested, fixed in 10%
formaldehyde, embedded in paraffin, and cut into sections 6 m thick. Tissue
sections were collected from atrial and ventricular regions, mounted on slides,
and postfixed in Bouin’s solution. After a series of xylene and alcohol washes
were performed, slides were stained with Weigert’s hematoxylin and Masson’s
trichrome staining solutions. Then, slides were subjected to increased concentrations of alcohol and xylene and mounted with Entellan.
Quantitative PCR. For RNA purifications, tissues were grounded in a potter
with a pestle with liquid nitrogen, and total RNA was extracted using Trizol. For
quantitative PCR (qPCR), total RNA was treated with DNase I (Ambion, Austin, TX), and first-strand cDNA was synthesized using the High-Capacity cDNA
transcription kit (Applied Biosystems, CA) according to the manufacturer’s
instructions. After reverse transcription, the cDNA was subjected to qPCR on a
7500 real-time PCR system (Applied Biosystems, CA) by using Power SYBR
green PCR master mix (Applied Biosystems, CA). Briefly, amplification was
carried out in a total volume of 20 l containing 0.5 M each primer, 10 l of
Power SYBR green master mix (2⫻), and 1 l of cDNA. The PCRs were cycled
45 times after initial denaturation (95°C, 2 min) with the following parameters:
95°C for 15 s, annealing at 60°C for 30 s, and extension at 72°C for 30 s. For each
experiment, a nontemplate reaction was included as a negative control. In addition, the absence of DNA contaminants was assessed in reverse transcriptasenegative samples. Melting curve analysis of amplification products was performed by cooling the samples to 60°C and then increasing the temperature to
95°C at 0.1°C/s. The specificity of the PCRs was also confirmed by size verification
of the amplicons in acrylamide gel. Relative quantification of gene expression was
done with the 2⫺⌬⌬CT method, using the ␤-actin gene expression to normalize the
data. Sequences of primers used are available upon request.
Immunofluorescence. Images were acquired with an Axiovert 200 M microscope coupled with the ApoTome system or a Leica SP5 confocal microscope to
obtain optical sections of the tissue. Objectives used were 20⫻ dry, 40⫻ water
immersion (1.2 numerical aperture [NA]), and 63⫻ oil immersion (1.4 NA).
Adult VAChT KDHOM and WT mice were anesthetized with ketamine and
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Although less abundant, parasympathetic fibers are also found
throughout the ventricles, where stimulation of M2-AChR by
ACh leads to L-type calcium channel inhibition and consequently reduced cardiomyocyte contractility (34).
Genetic disturbance of cholinergic neurotransmission in animal models is complicated, due to the requirement of ACh release to sustain motor function. Thus, the consequences of chronically reduced cholinergic neurotransmission for long-term
cardiac function and molecular remodeling have not been studied
in detail until now. Given the abundance of acetylcholine receptors, it is likely that genetic disturbance of individual receptors
may not reveal all the consequences of decreased cholinergic
tone. We have recently generated a mouse model of cholinergic dysfunction (VAChT knockdown, homozygous [VAChT
KDHOM]) by targeting using homologous recombination for
the vesicular ACh transporter (VAChT), a protein responsible
for packaging ACh in secretory vesicles (41). VAChT KDHOM
mice have an approximately 70% reduction in the levels of
VAChT (41). Here, we used this unique mouse model to investigate whether long-term reduction of cholinergic neurotransmission affects cardiac physiology.
The present studies demonstrate that autonomic imbalance,
due to chronic decrease of cholinergic neurotransmission in
VAChT mutant mice, is associated with altered gene expression
that underlies a heart dysfunction phenotype. Additionally, we
show that enhancement of cholinergic activity is beneficial in
improving cardiac alterations in VAChT mutant mice. Our findings provide novel insights on mechanisms and compensatory
changes found in hearts subjected to prolonged alterations in
autonomic regulation. These data support the notion that the
cholinergic system is an important pharmacological target in
heart failure.
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FIG. 1. VAChT mutant mice present heart failure. (A) VAChT
and CHT1 immunoreactivity in neurons of adult WT and VAChT
KDHOM mouse intracardiac ganglia. Note the reduction in immunofluorescence for VAChT. There was no decrease in immunoreactivity
in nodal ganglia of VAChT KDHOM stained with an antibody against
the high-affinity choline transporter (CHT1). Blue labeling corresponds to nuclei stained with DAPI that seem to predominantly label
glial cells. Arrowheads indicate some of the neuronal cell bodies in the
ganglia. Bar ⫽ 20 m. (B) Left ventricle function (as assessed by
contractility index) in VAChT KDHOM mice (black bars) and WT mice
(white bars). VAChT mutant mouse hearts had decreased contractility
indexes and lower absolute responses to ISO. n, number of mice; ⴱ, P
value of ⬍0.05 in comparison with the WT.

RESULTS
Decreased cholinergic neurotransmission in VAChT KDHOM
mice causes heart failure. VAChT KDHOM mice have previously been shown to have reduced VAChT expression and
altered ACh release (41; R. F. Lima, V. F. Prado, M. A. Prado,
and C. Kushmerick, submitted for publication). In agreement
with these previous observations, hearts from 3-month-old
VAChT KDHOM mice had decreased VAChT immunoreactivity
in intracardiac ganglia (Fig. 1A; arrowheads indicate some of the
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xylazine (70 and 10 mg/kg i.p., respectively) and transcardially perfused with
ice-cold phosphate-buffered saline (PBS), pH 7.4, for 10 min, followed by an
ice-cold solution of methanol containing 20% dimethyl sulfoxide (DMSO) for 10
min. Immunofluorescence was performed as previously described (10). Slices
were incubated for 15 to 18 h with primary antibodies anti-VAChT (rabbit
polyclonal, 1:250; Sigma Chemical Co., São Paulo, Brazil) and CHT1 (rabbit
polyclonal, 1:250; kindly provided by R. Jane Rylett, University of Western
Ontario, London, Ontario, Canada).
Immunofluorescence of adult ventricular cardiomyocytes was performed on cells
fixed in 4% paraformaldehyde (PFA) and permeabilized with 0.5% saponin. Anti␣-actinin antibody (Sigma) was used at a dilution of 1:200. Secondary antibodyconjugated to Alexa Fluor 488 or 543 (Molecular Probes) was used at a dilution of
1:1,000, and nuclear staining was performed using DAPI (4⬘,6-diamidino-2-phenylindole) in a dilution of 1:1,000. Cardiomyocyte cellular area in ␣-actinin-stained cells
was measured.
Cardiomyocyte morphometry. The mice were anesthetized with 10% ketamine–2% xylazine (4:3, 0.1 ml/100 g, i.p.), and heartbeat was stopped in
diastole by using 10% KCl (intravenous [i.v.]). Hearts were placed in 4% Bouin’s
fixative for 24 h at room temperature. The tissues were dehydrated by sequential
washes with 70, 80, 90, and 100% ethanol and embedded in paraffin. Transversal
sections (5 m) were cut starting from base area of the heart at intervals of 40
m and stained with hematoxylin-eosin for cell morphometry. Tissue sections (2
from each animal) were examined with a light microscope (BX 41; Olympus) at
⫻400 magnification, photographed (Q Color 3; Olympus), and analyzed with
ImageJ software. Only digitized images of cardiomyocytes cut longitudinally with
nuclei and cellular limits visible were used for analysis (an average of 40 cardiomyocytes for each animal). The diameter of each myocyte was measured across
the region corresponding to the nucleus.
Whole-heart morphometry. Transversal heart sections (5 m) were cut starting from base area of the heart at intervals of 40 m and stained with
hematoxylin-eosin. The area of cardiac mass was obtained by subtracting the
left and right ventricle chamber areas from the total area of the heart and
expressed as a percentage of the total area. Images with ⫻20 magnification
were captured using a Q Color 3 camera (Olympus) to measure ventricular
and total tissue areas.
Whole-cell patch clamp and action potential recordings. An EPC-9.2 instrument (HEKA Electronics) was used to patch clamp single ventricular cardiomyocytes in whole-cell voltage and current clamp configurations, using specific
protocols according to the ionic conductance evaluated (8, 36, 42). Measurements started 5 min after breaking into the cell in order to attain equilibrium
between the pipette solution and the cell cytoplasm. For action potential (AP)
recordings, the pipette solution consisted of 130 mmol/liter K-aspartate, 20
mmol/liter KCl, 10 mmol/liter HEPES, 2 mmol/liter MgCl2, 5 mmol/liter NaCl,
and 5 mmol/liter EGTA (set to pH 7.2 with KOH). Modified Tyrode used as bath
solution contained 140 mmol/liter NaCl, 5.4 mmol/liter KCl, 1 mmol/liter MgCl2,
1.8 mmol/liter CaCl2, 10 mmol/liter HEPES, and 10 mmol/liter glucose (set at pH
7.4). Current injections triggered action potentials at a constant rate (1 Hz).
For L-type Ca2⫹ current (ICa,L) recordings, the pipette solution contained 120
mM CsCl, 20 mM tetraethylammonium chloride (TEACl), 5 mM NaCl, 10 mM
HEPES, 5 mM EGTA (set to pH 7.2 with CsOH). The bath solution was
modified Tyrode solution. ICa was elicited by depolarization steps from ⫺40 to 50
mV for 300 ms from a holding potential of ⫺80 mV at a frequency of 0.1 Hz and
sample frequency of 10 kHz. To inactivate Na⫹ current (INa), we used a prepulse
from ⫺80 to ⫺40 mV with a duration of 50 ms. ␤-Adrenergic stimulation of cells
was produced by the addition of 100 nmol/liter isoproterenol to modified Tyrode
solution for 3 min. All experiments were carried out at room temperature (23 to
26°C).
Western blotting. Forty to 60 g of protein was separated by SDS-PAGE.
Antibodies used were anti-SERCA2 and antiphospholamban (anti-PLN) (ABR),
anti-phospho-PLN (Ser-16) (Upstate), anti-phospho-PLN (Thr-17) (Badrilla),
anti-troponin I (TnI) and anti-phospho-TnI (Cell Signaling), and anti-␣-tubulin
(Sigma Chemical Co.). Immunodetection was carried out using enhanced chemiluminescence (Amersham Biosciences). Protein levels were expressed as ratios
of optical densities. ␣-Tubulin was used as a control for any variations in protein
loading.
Statistical analysis. All data are expressed as means ⫾ standard errors of the
means (SEM), and the numbers of cells or experiments (n) are shown. Significant
differences between groups were determined with Student’s t test or an analysis
of variance (ANOVA) followed by the Bonferroni post hoc test. P values of
⬍0.05 were considered to be statistically significant.
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TABLE 1. Hemodynamic parameters for WT and VAChT KDHOM mice under baseline and isoproterenol stimulation conditionsa
Baselineb
Parameter

HR (bpm)
LVSP (mm Hg)
LVEDP (mm Hg)
⫹dP/dtmax (mm Hg/s)
⫺dP/dtmin (mm Hg/s)

Isoproterenolb

WT

VAChT KDHOM

WT

VAChT KDHOM

277 ⫾ 26
104.0 ⫾ 2.4
8.3 ⫾ 1.7
7,245 ⫾ 388
6,739 ⫾ 478

240 ⫾ 15
86.2 ⫾ 6.0*
11.8 ⫾ 2.4
4,640 ⫾ 573*
4,591 ⫾ 637*

621 ⫾ 22
111.8 ⫾ 10.9
1.2 ⫾ 1.2
16,615 ⫾ 866
9,163 ⫾ 436

509 ⫾ 43*
90.7 ⫾ 4.4
7.5 ⫾ 2.0*
10,798 ⫾ 1,295*
6,448 ⫾ 375*

neuronal cell bodies) compared to the WT. In contrast, there was
no decrease in immunoreactivity in VAChT KDHOM mouse
nodal ganglia stained with an antibody against the high-affinity
choline transporter (CHT1). These results confirm previous assessments of VAChT and CHT1 expression in VAChT KDHOM
mice (10, 41). We have shown previously that a constitutively lack
of cholinergic tone affects skeletal muscle function and ability to
perform exercise in VAChT KDHOM mice (41). Moreover, the
lack of VAChT in KO mice affects skeletal muscle development
(9). In order to determine if the constitutive decrease in cholinergic tone could affect cardiomyocytes and, hence, heart physiology, we performed invasive hemodynamic assessments on anesthetized mice. These experiments revealed a reduced contractility
index (maximum first derivative of the change in left ventricle
pressure [dP/dt] divided by the LV pressure at the time of maximum dP/dt) in the hearts of 3-month-old VAChT KDHOM mice
compared to that of WT controls (Fig. 1B). Peak left ventricle
systolic pressure and the maximum rates of LV pressure rise and
fall (peak ⫹dP/dt and ⫺dP/dt, respectively) were also significantly
lower in VAChT mutants than in WT mice under baseline conditions (Table 1). Furthermore, an attenuated response to ISO by
VAChT mutants was evident (Fig. 1B and Table 1). Although the
absolute effect shows a decrease in the ISO-mediated response by
VAChT mutants, the relative increases in contractility index were
not significantly different between WT and VAChT mutants. In
order to investigate the progression of cardiac dysfunction in
VAChT mutants, we have also performed hemodynamic assessments of 1-month-old VAChT mutant mice. In contrast to
3-month-old mice according to the obtained data, younger mice
did not show differences in the contractility index under either
baseline (WT, 134 ⫾ 22 s⫺1 [n ⫽ 4]; VAChT KDHOM, 135 ⫾ 6
s⫺1 [n ⫽ 5]) or maximal ISO stimulation (WT, 251 ⫾ 17 s⫺1 [n ⫽
4]; VAChT KDHOM, 303 ⫾ 24 s⫺1 [n ⫽ 5]) conditions. Therefore,
all subsequent experiments were performed with 3-month-old
mice.
To ascertain the extension of cardiac dysfunction in
3-month-old VAChT KDHOM mice “in vivo,” we performed
two-dimensional M-mode echocardiography. As shown in Fig.
2A, VAChT KDHOM mice displayed reduced left ventricle
fractional shortening, consistent with the heart dysfunction
illustrated in Fig. 1B. To further confirm that the decreased
baseline fractional shortening was indeed the result of altered
cholinergic function in vivo, we treated VAChT KDHOM mice
for 2 weeks with a cholinesterase inhibitor, with the rationale
that pharmacological restoration of ACh at synapses might
rescue the phenotype and improve cardiac function in mutant
mice. Administration of pyridostigmine for 2 weeks signifi-

cantly increased fractional shortening of VAChT KDHOM mice
toward control levels (Fig. 2A). To further assess directly the
heart dysfunction in VAChT KDHOM mice without the complication of extensive regulation by the autonomic nervous
system, we used the Langerdorff isolated heart preparation. In
agreement with the results obtained with echocardiography
studies, isolated hearts from VAChT KDHOM mice had significantly decreased systolic tension compared to WT hearts (Fig.
2B). Pyridostigmine treatment of animals for 2 weeks also
reversed the decreased systolic tension in isolated VAChT
KDHOM hearts measured in vitro. Similarly, a contractile dysfunction was observed in isolated adult ventricular cardiomyocytes from VAChT KDHOM mice, which demonstrated reduced fractional shortening compared to cardiomyocytes from
WT mice (see Fig. S1A in the supplemental material).
In agreement with the data showing heart dysfunction in
VAChT KDHOM mice, transcripts encoding atrial natriuretic
factor (ANF), ␤-myosin heavy chain (␤-MHC), and B-type
natriuretic peptide (BNP), markers of cardiac stress, were also
upregulated in cardiomyocytes from VAChT mutants. These
changes were reversed by pyridostigmine treatment, suggesting
that they are triggered by reduced cholinergic neurotransmission (Fig. 2C).
One possible reason for the alteration in cardiac function in
VAChT KDHOM mice might be related to an increase in blood
pressure or HR. Contrary to this prediction, decreased cholinergic tone in VAChT KDHOM mice was associated with reduced arterial pressure (see Fig. S1B in the supplemental material), with no significant alteration in basal HR using the
tail-cuff system (715 ⫾ 9 bpm for WT mice [n ⫽ 17] versus
698 ⫾ 10 bpm for VAChT KDHOM mice [n ⫽ 16]). Similarly,
no significant differences were observed in HR as determined
by telemetry comparing WT and VAChT KDHOM mice (530 ⫾
45 bpm for WT mice [n ⫽ 3] versus 615 ⫾ 26 bpm for KDHOM
mice [n ⫽ 3]; P ⫽ 0.18). Additionally, HRs of VAChT KDHOM
and WT mice under anesthesia were not significantly different
(Table 1), and this contrasted with significantly reduced HRs
recorded from ex vivo beating hearts from VAChT KDHOM
mice compared to those from WT controls (Fig. 2D).
Importantly, heart dysfunction observed in VAChT mutant
mice was not linked to cardiac fibrosis (see Fig. S1C in the
supplemental material) and hypertrophy. Instead, cardiac mass
(Table 2), morphometric analyses of cross-sectional area (see
Fig. S1D in the supplemental material), and cellular area measurements (1,992.0 ⫾ 78.5 m2 cell area in WT mice [29 cells]
versus 1,318.0 ⫾ 60.4 m2 in VAChT KDHOM mice [40 cells];
P ⬍ 0.05) indicated that both the heart and cardiomyocytes
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a
HR, heart rate; LVSP, left ventricle systolic pressure; LVEDP, left ventricle end diastolic pressure; ⫹dP/dtmax, maximum first derivative of the change in left
ventricle pressure; ⫺dP/dtmin, minimum first derivative of the change in left ventricle pressure; ⴱ, P value of ⬍0.05 in comparison to the wild-type value.
b
Values are means ⫾ SEM (n ⫽ 6).
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TABLE 2. Phenotypic parameters for WT and
VAChT KDHOM micea
Parameter

WT (n ⫽ 23)b

KDHOM (n ⫽ 26)b

BW (g)
HW (mg)
HW/TL ratio (mg/mm)

24.26 ⫾ 0.51
193.50 ⫾ 4.82
8.80 ⫾ 0.25

22.53 ⫾ 0.36
177.30 ⫾ 4.36
7.96 ⫾ 0.16

a

BW, body weight; HW, heart weight; HW/TL, heart weight/tibia length ratio.
Values are means ⫾ SEM. The P values were ⬍0.05 for all conditions in
comparisons of the values for the wild-type and VAChT KDHOM mice.
b
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FIG. 2. Pyridostigmine treatment prevented cardiac dysfunction in
VAChT KDHOM mice. (A) Echocardiography analysis of left ventricle
fractional shortening (FS) in VAChT mutant mice (black bars) and
WT mice (white bars). Note the significant improvement in left ventricle performance after pyridostigmine treatment (gray bars). n, number of mice. (B) Time course of systolic tension in isolated perfused
hearts from WT (white squares; 15 hearts) and VAChT KDHOM (black
squares; 16 hearts) mice. Pyridostigmine treatment improved systolic
tension of hearts from mutant mice (gray squares; 4 hearts). (C) Gene
expression of stress cardiac markers in cardiomyocytes from VAChT
KDHOM mice and WT mice. The bar graph shows data from at least 5
independent experiments. a.u., arbitrary units. (D) The HR measured
in ex vivo beating hearts from VAChT KDHOM mutants (black squares)
was lower than that of WT hearts (white squares) after 40 min of
perfusion. Pyridostigmine treatment for 2 weeks (gray squares) prevented the observed changes in HR. (E) (Top) Representative confocal images of electrically stimulated intracellular Ca2⫹ transient recordings in ventricular myocytes. (Bottom) Ca2⫹ transient line-scan
profile. (F) Significant reduction in peak Ca2⫹ transient amplitude
observed in freshly isolated adult VAChT KDHOM ventricular cardiomyocytes compared to the amplitude for WT mice. Pyridostigmine
treatment significantly prevented intracellular Ca2⫹ dysfunction in
VAChT KDHOM mice. n, number of ventricular cardiomyocytes analyzed. (G) Ca2⫹ transient kinetics of decay in VAChT KDHOM cardiomyocytes and WT mice. Note that the observed changes in myocytes
from VAChT KDHOM mice can be prevented by 2 weeks of pyridostigmine treatment. ⴱ, P value of ⬍0.05 in comparison with WT and
KDHOM PYR mice. T50, time from peak Ca2⫹ transient to 50% decay.

from VAChT mutant were significantly smaller than those of
the WT mice at 3 months. However, it is possible that hypertrophy may develop or progress in mutant hearts as a result of
depressed cholinergic drive with age. In fact, hearts from
6-month-old mutants presented more pronounced changes in
cardiac structure characterized by concentric hypertrophy
compared to age-matched controls (see Fig. S1E and F in the
supplemental material). Taken together, these data suggest
that VAChT mutants have progressive changes in cardiac
mass. Herein, we focused our experiments on 3-month-old
mice.
Altered Ca2⫹ handling can influence cardiomyocyte physiology and changes in intracellular Ca2⫹ are a major feature in
heart failure and myocyte pathology (3, 4). To determine if the
heart dysfunction detected in VAChT KDHOM mice is related
to changes in Ca2⫹ handling, we examined intracellular Ca2⫹
in freshly isolated Fluo-4 AM-loaded ventricular myocytes
from 3-month-old VAChT KDHOM and WT mice. Figure 2E
displays typical line-scan fluorescence images recorded from
electrically stimulated ventricular myocytes. VAChT KDHOM
cardiomyocytes developed significantly smaller and slower intracellular Ca2⫹ transients than WT cells. The amplitude of the
Ca2⫹ transient was significantly reduced in VAChT KDHOM cardiomyocytes (Fig. 2F), and the kinetics of Ca2⫹ decay were
significantly slower (Fig. 2G). These changes are closely related to the alteration in cholinergic tone in VAChT mutant
mice, as Ca2⫹ handling is restored to normal levels in cells
obtained from pyridostigmine-treated VAChT KDHOM mice.
Hence, changes in intracellular calcium handling parallel alterations in cardiac function due to reduced cholinergic tone.
Collectively, these results suggest a correlation between decreased cholinergic tone and heart dysfunction that can be
recovered by cholinesterase inhibitor treatment.
Cardiomyocyte remodeling in VAChT KDHOM mice. To investigate the cellular basis of the abnormal intracellular Ca2⫹
transient of failing VAChT KDHOM cardiomyocytes, electrical
activity and expression levels of Ca2⫹ handling proteins were
assessed by electrophysiology and Western blotting techniques,
respectively. First, we investigated whether possible changes in
ICa may play a role in the Ca2⫹ signaling dysfunction observed
in VAChT KDHOM cardiac cells. Figure 3A shows sample ICa
recordings. Virtually no difference between macroscopic ICa
values recorded in VAChT KDHOM and WT cells was observed (at 0 mV, ⫺8.10 ⫾ 0.44 pA/pF in 12 WT cardiomyocytes
versus ⫺7.98 ⫾ 0.39 pA/pF in 20 VAChT KDHOM cardiomyocytes) (Fig. 3B), suggesting that under basal conditions, Ca2⫹
currents of the two genotypes were identical. Activation of
␤1-adrenergic receptor increases ICa, and this is in part responsible for the adrenergic regulation of myocytes. Although we
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have not observed a significant change in ISO-mediated response in vivo, it is possible that at the cellular level, ␤-adrenergic responses are altered; therefore, we next evaluated ICa
levels in myocytes exposed to ISO (100 nM). Figure 3A to C
show that the ICa increase induced by ISO was much less
prominent in VAChT KDHOM ventricular myocytes.
Alterations in action potential profile may also contribute to
dampening Ca2⫹ cycling in ventricular cells. To investigate this
possible contribution, we recorded action potentials in ventricular myocytes from WT and VAChT KDHOM mice. No change
between the action potential profiles of these cells was observed (Fig. 3D and E), indicating that electrical changes were
not contributing to the Ca2⫹ signaling dysfunction observed in
response to decreased cholinergic tone.
The slow decline of the Ca2⫹ transient in VAChT KDHOM
cardiomyocytes is consistent with the decreased expression of
the sarcoplasmic reticulum (SR) Ca2⫹ pump (SERCA2);
therefore, we examined SERCA2 levels in these hearts. A
significant reduction in SERCA2 expression levels was observed in VAChT KDHOM hearts (Fig. 4A) compared to WT
controls. In cardiac cells, PLN is the primary determinant of
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FIG. 4. Ca2⫹ signaling components in VAChT KDHOM hearts. In
panels A to D, the top image is a representative Western blot and the
bottom shows an average densitometry graph (n, number of heart
samples analyzed). (A) SERCA2 levels in VAChT KDHOM hearts
were observed to be significantly reduced compared to levels in WT
hearts. Phosphorylated-PLN levels at the protein kinase A (PKA)dependent site (Ser-16) were lower in VAChT mutant hearts (B),
while phospho-Thr-17-PLN levels were increased in these hearts (C).
(D) Phospho-Ser-23/24-troponin I levels were decreased in VAChT
mutant hearts relative to WT hearts. Tubulin expression levels were
used as a loading control. (E) The SR Ca2⫹ content in ventricular
cardiomyocytes from VAChT mutants was significantly reduced compared to that in WT cells. n, number of cells. (F) Ca2⫹ spark frequency
showed a tendency to be lower in VAChT KDHOM cardiomyocytes
than in WT mice, but the difference was not statistically different. n,
number of cells. ⴱ, P ⬍ 0.05.

SERCA2 function. Therefore, we also investigated if there
may be a change in PLN activity in VAChT KDHOM hearts by
examining PLN expression/phosphorylation levels in these
hearts. PLN expression was higher in VAChT KDHOM hearts
(data not shown); however, as shown in Fig. 4B, phosphorylated-PLN levels at Ser-16, a key determinant of SERCA2
activity, were significantly reduced in these hearts. We have
also assessed PLN phosphorylation levels at the CaMKII site
(Thr-17). Phospho-Thr-17-PLN levels in VAChT KDHOM
hearts were significantly increased compared to those in WT
hearts (Fig. 4C). Another important aspect of cardiac cells is
the sensitivity of the myofilaments to Ca2⫹. Since TnI phosphorylation desensitizes the myofilament to Ca2⫹, we next
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FIG. 3. Electrical properties of VAChT KDHOM cardiomyocytes.
(A) Sample ICa currents recorded from depolarizations from ⫺40 mV
to 0 mV. ISO (100 nmol/liter) significantly increased the magnitude of
ICa in WT cells but not in VAChT KDHOM ventricular myocytes.
(B) Average I-V relationships for ICa current density recorded from
WT mice (open circles), WT mice with ISO (gray circles), VAChT
KDHOM mice (black triangles), and VAChT KDHOM mice with ISO
(open triangles). (C) Steady-state activation curves. (D) Sample action
potential recordings from WT and VAChT KDHOM ventricular cardiomyocytes. (E) Action potential durations at 10, 30, 50, 70, and 90%
repolarization. Fifteen cells from each experimental group were used.
ⴱ, P value of ⬍0.05 in comparison with WT mice.
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assessed TnI phosphorylation levels in cardiac samples. As
shown in Fig. 4D, phospho-Ser-23/24-troponin I levels were
significantly decreased in VAChT KDHOM hearts compared to
WT hearts.
Since the SERCA2/PLN ratio is altered in the VAChT
KDHOM hearts, we next examined the possibility that this
alteration may lead to a reduction of Ca2⫹ in the SR. Figure
4E shows a significant reduction in SR Ca2⫹ content in
VAChT KDHOM cardiomyocytes. Furthermore, Ca2⫹ sparks
were less frequent in VAChT KDHOM cardiomyocytes than in
WT mice (Fig. 4F), although the data just failed to reach
statistical significance.
VAChT KDHOM mice show altered autonomic control of
heart rate and G-protein-coupled receptor (GPCR) function.
A chronic decrease in cholinergic tone in VAChT KDHOM
mice appears to cause molecular cardiac remodeling with alterations in expression of genes related to cardiac stress, Ca2⫹
handling, and muscle contractility. Moreover, data from recordings of calcium currents suggested that ␤1-adrenergic receptor responses are altered in VAChT KDHOM cardiomyocytes. To determine if decreased cholinergic tone, caused by
reduced release of ACh in VAChT mutant mice, affected the
responses to muscarinic and adrenergic activation, we treated
Langendorff preparation-perfused hearts with ACh or ISO. As
shown in Fig. 5A, hearts from VAChT KDHOM mice were
much more sensitive to ACh (13 mol/liter) than hearts from
WT mice, and they showed enhanced bradycardia in response
to this neurotransmitter. In contrast, the contractility response
of ex vivo beating hearts from VAChT KDHOM mice to ISO
(10 mol/liter) was significantly attenuated (Fig. 5B), providing additional evidence of altered adrenergic response in mutant hearts.
To examine the possibility of autonomic imbalance in
3-month-old VAChT KDHOM mice in vivo, we assessed the
effects of muscarinic and adrenergic receptor blockades on HR
and HR variability parameters. Administration of atropine did
not significantly increase HRs in either WT (⌬HR, 56 ⫾ 27
bpm) or VAChT KDHOM (⌬HR, 65 ⫾ 28 bpm) mice, whereas
propranolol administration significantly reduced the HR in
VAChT KDHOM mice (⌬HR, ⫺115 ⫾ 27 bpm; P ⬍ 0.05) but
not in WT mice (⌬HR, ⫺78 ⫾ 40 bpm). Interestingly, the
coadministration of atropine and propranolol resulted in a
significant reduction of HR in VAChT KDHOM mice (⌬HR,
⫺87 ⫾ 13 bpm; P ⬍ 0.05) but not in WT mice (⌬HR, ⫺11 ⫾ 4

bpm). These results would suggest that HR in VAChT KDHOM
mice is under increased sympathetic control relative to HR in WT
mice. To further investigate autonomic imbalance, we examined
HRV parameters. Under baseline conditions, no significant differences in very low frequency (VLF) and low frequency (LF)
power spectrum of HRV between WT and VAChT KDHOM mice
were observed (data not shown). However, high-frequency (HF)
power was significantly increased in VAChT KDHOM mice (HF,
3.66 ⫾ 0.18 ms2; n ⫽ 3) compared to WT mice (HF, 1.98 ⫾ 0.42
ms2; n ⫽ 3), which resulted in a significant difference between the
LF/HF ratios of the genotypes (4.2 ⫾ 0.6 for KDHOM mice [n ⫽
3] versus 6.6 ⫾ 0.5 for WT mice [n ⫽ 3]; P ⫽ 0.04). Atropine
administration significantly reduced the LF/HF ratio in both WT
(1.2 ⫾ 0.5; n ⫽ 3) and VAChT KDHOM (1.6 ⫾ 0.8; n ⫽ 3) mice,
and these values were not different between genotypes. Interestingly, propranolol treatment did not significantly alter the LF/HF
ratios relative to the baseline LF/HF ratios for either WT or
VAChT KDHOM mice (data not shown). Lastly, the coadministration of atropine and propranolol significantly reduced the
LF/HF ratios in both WT (2.1 ⫾ 1.1; n ⫽ 3) and VAChT KDHOM
(0.9 ⫾ 0.5; n ⫽ 3) mice, and these values were not different
between genotypes. Taken together, these experiments suggested
the possibility that decreased cholinergic tone causes an imbalance of autonomic control of the heart, characterized by altered
GPCR activation, with sympathetic tone in VAChT KDHOM
mice being at a higher level than that in WT mice.
To determine the molecular basis of these changes in GPCR
activation, we measured transcript expression levels of muscarinic and adrenergic receptors or associated proteins (such as
GPCR kinases [GRKs]). Real-time quantitative PCR analysis
of RNA from heart tissue indicated that M2 muscarinic receptor levels were overexpressed (by 2-fold) in VAChT KDHOM
hearts (Fig. 6A). In contrast, ␤1-adrenergic receptor transcripts
were decreased by 41% in VAChT mutant hearts compared to
the expression of WT controls (Fig. 6B). This reduction is
consistent with attenuated magnitude of ISO-induced increment in ICa in VAChT KDHOM cardiomyocytes (Fig. 3B) and
the reduced ISO response of VAChT mutants observed ex vivo
(Fig. 5B). Interestingly, pharmacological restoration of ACh
with pyridostigmine treatment for 2 weeks reversed the overexpression of M2 receptor message in VAChT KDHOM hearts,
but it did not reverse the decrease in the levels of ␤1-adrenergic receptor message. Finally, we examined if we could detect
transcripts for muscarinic receptors in isolated adult ventricular cardiomyocytes. We found an increase in M2 muscarinic
receptors in cardiomyocytes similar to what we found in the
whole heart, but we also found that M1 and M3 transcripts,
which have been shown to have a role in inotropic responses
(25, 45, 49), were also overexpressed in VAChT KDHOM mice
(Fig. 6C).
To further confirm if reduced ACh release could alter
GPCR message levels, we measured M2 and ␤1 receptor messages in recently developed VAChT KO mice (VAChTdel/del
[9]). Homozygous VAChT KO mice are unable to release
acetylcholine in response to depolarization and died shortly
after birth due to respiratory failure (9). We examined hearts
from embryos (day 18.5) of VAChTdel/del mice and found that
they recapitulate the molecular changes in GPCRs levels found
in adult VAChT KDHOM mice, i.e., mRNA levels of M2 muscarinic receptors were significantly increased, while the mRNA
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FIG. 5. VAChT KDHOM hearts present an altered GPCR response. (A) Percent decrease in beating frequency for WT (white
squares; n ⫽ 4) and VAChT KDHOM (black squares; n ⫽ 4) hearts in
response to 13 mol/liter ACh. (B) Time course of mean percent force
increase in WT (n ⫽ 5) and VAChT KDHOM (n ⫽ 5) perfused hearts
in response to 10 mol/liter ISO.
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FIG. 6. Effect of VAChT deficiency on M2 muscarinic and ␤1adrenergic receptor message levels. M2 muscarinic and ␤1-adrenergic
receptor message levels were determined by qPCR. n, number of heart
samples. (A) M2 mRNA levels were significantly increased in VAChT
KDHOM hearts. (B) Significant reduction in ␤1-adrenergic receptor
mRNA levels was observed in VAChT KDHOM hearts. Pyridostigmine treatment prevented the increase in M2 mRNA levels without
affecting ␤1-adrenergic receptor mRNA expression levels in VAChT
KDHOM hearts. (C) Determination of M1 to M5 mRNA expression
levels by real-time quantitative PCR in ventricular cardiomyocytes
from WT and VAChT KDHOM mice. Significant levels of M1 to M3
transcripts were detected in cardiomyocytes from WT mice. M1, M2,
and M3 muscarinic receptor transcript levels were upregulated in
VAChT KDHOM cardiomyocytes. The bar graph represents data from
at least 6 independent experiments. ⴱ, P ⬍ 0.05. (D and E) Increased
M2 and reduced ␤1-adrenergic receptor transcript messages are observed in hearts of VAChT knockout mice. ⴱ, P value of ⬍0.05 in
comparison with the WT; †, P value of ⬍0.05 in comparison with
KDHOM mice treated with PYR. n, number of heart samples analyzed.

levels of ␤1-adrenergic receptors were decreased in VAChTdel/del
mice compared to the WT (Fig. 6D and E). Thus, in two distinct
strains of mutant mice with altered expression of VAChT, we
detected similar gene expression patterns of GPCRs. Alterations
in GRK expression levels have the potential to affect GPCRstimulated biological responses, and GRKs have been shown
to be altered in heart failure (40). Therefore, we measured
GRK message levels in hearts of VAChT KDHOM mice, with
particular attention to GRKs that have been previously shown
to phosphorylate ␤-adrenergic or M2 receptors and participate
in receptor desensitization. The message of GRK2, the mostexpressed GRK in cardiac tissue, was increased in VAChT
KDHOM hearts compared to WT controls (by 84%). We also
observed a significant increase in GRK5 message levels (by
44%), whereas GRK3 levels were not altered in VAChT
KDHOM hearts. Moreover, GRK6 expression levels in VAChT

KDHOM hearts were reduced by 17% compared to those in
WT hearts. Figure 7 summarizes these data. Hence, the alteration in receptor responses may reflect a combination of receptor and GRK changes in hearts of VAChT mutants.
DISCUSSION
In this work, we present evidence that chronic disturbance in
cholinergic tone in mutant mice causes changes in cardiac gene
expression associated with a molecular remodeling with altered intracellular calcium handling and decreased ventricular
function. The dysautonomy due to decreased VAChT expression causes pronounced alterations in autonomic receptor
function, with attenuated ␤1-receptor responses, whereas M2
responses seem exacerbated. Moreover, the cardiac phenotype
of VAChT KDHOM mice could be reversed by treatment with
a cholinesterase inhibitor, pyridostigmine. These data suggest
that cholinergic transmission might have unanticipated roles in
maintaining ventricular cardiac contractility and that decreased cholinergic tone may contribute to cardiac dysfunction.
Clinical studies have shown that withdrawal of parasympathetic tone precedes sympathetic activation during the development of heart failure (1). For humans, spectral analysis
suggests that aging, one of the major risk factors for heart
failure, decreases parasympathetic drive (11). Animal studies
further corroborated these data by showing autonomic imbalance in the early stage of experimental heart failure in dogs
(22). Thus, dysautonomy plays important roles in pathological
changes in the heart (37). However, given that genetic interference in the presynaptic cholinergic system is usually fatal, it
has been difficult to chronically disturb the cholinergic autonomic nervous system to understand if acetylcholine plays any
unanticipated roles in cardiac contractility.
VAChT presence in synaptic vesicles is fundamental for
evoked release of ACh, as VAChT KO mice cannot release
this neurotransmitter (9), and the VAChT KDHOM mice,
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FIG. 7. GRK message expression levels are altered in VAChT mutant hearts. Determination of GRK2 (A), GRK3 (B), GRK5 (C), and
GRK6 (D) mRNA expression by real-time quantitative PCR. n, number of hearts analyzed. ⴱ, P ⬍ 0.05.
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tants, even though parasympathetic fibers are not abundant in
ventricles of rodents (30). Therefore, ACh may control ventricular cell function by mechanisms that are not characterized
yet, and disturbance of VAChT expression can interfere with
ventricular function. In fact, the possibility that cardiomyocytes
express presynaptic cholinergic proteins has been raised recently (23).
It is well established that acetylcholine controls atrial function, with predominant roles in maintaining heart rate and
action potential conduction. Unexpectedly, we found that altered cholinergic tone also provokes profound effects on ventricular cardiomyocytes. The array of cellular changes included
Ca2⫹ signaling dysfunction and altered GPCR function. Interestingly, these changes occurred without altering ICa density or
action potential properties. Overall, the cardiac remodeling
observed for VAChT mutant mice resembles in many aspects
the remodeling process observed for animal models of heart
failure with sympathetic overdrive (7, 19, 39). Therefore, we
suggest that the autonomic imbalance in the sympathetic direction in VAChT mutants, with decreased parasympathetic
activity, can largely explain the development of ventricular
dysfunction in these mice.
It is not clear at the moment if the overexpression of M2
muscarinic receptors contributes to the VAChT cardiac phenotype. We found that hearts from VAChT mutants were
more sensitive to the bradycardic effects of ACh, suggesting
the presence of increased functional M2 receptors in these
hearts. It is well known that M2 receptors couple to the Gi/0
family of G proteins (27) to inhibit adenylyl cyclase; therefore,
it is likely that M2 overexpression may also contribute to the
impaired ␤1 response in VAChT mutant hearts. Consistent
with this notion, improvement in ventricular function following
pyridostigmine treatment of VAChT mice occurred in spite of
reduced ␤1-receptor mRNA levels. It remains to be determined if attenuation of ␤1-adrenergic receptor mRNA in this
model is a late event that may require more-prolonged pyridostigmine treatment. Levels of GRK2 are elevated in different models of heart failure characterized by enhanced chronic
neurohumoral stimulation, in which they contribute to ␤1-adrenergic receptor attenuation (39). Consistent with this notion,
we found increased GRK2 levels in the VAChT mutant model
of cholinergic deficiency. Our results also demonstrated an
upregulation of GRK5 in VAChT mutant hearts. Recently,
Martini and collaborators (31) have characterized a new role
for GRK5 as a nuclear histone deacetylase (HDAC) kinase
with a key role in maladaptive cardiac hypertrophy. In this
context, nuclear accumulation of GRK5 correlates with enhanced ventricular expression of the hypertrophy-associated
fetal gene program (31). It is interesting that 3-month-old
VAChT KDHOM mice had no sign of cardiac hypertrophy,
although they showed increased levels of ANF and ␤-MHC
transcripts. However, it is important to mention that ventricular expression of these markers is not always associated with
cardiac hypertrophy (38, 48). In contrast, 6-month-old mice
presented concentric hypertrophy, suggesting that cardiac dysfunction is progressive in VAChT mutant hearts as a result of
chronic depressed cholinergic drive with age. It remains to be
determined whether aged VAChT KDHOM mice will present
further features of heart failure. Another critical aspect of
cardiac dysfunction in heart failure is ventricular dyssynchrony.
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which present reduced VAChT expression, show reduced ACh
packing in synaptic vesicles (41). It is likely that both the
sympathetic and parasympathetic nervous systems are affected
in VAChT KDHOM mice, since both depend on preganglionic
cholinergic neurotransmission, albeit the parasympathetic nervous system should be hit twice due to its postganglionic cholinergic phenotype. We favor the possibility that dysautonomy
caused by decreased cholinergic tone results in imbalance of
autonomic control of the heart in mutant mice, based on the
following evidence. First, it is known that at room temperature
(25°C), the sympathetic drive predominates in mice and keeps
their heart rate high (18). We found that heart rates were
identical in the two genotypes despite a substantial decrease in
␤1-receptor expression and function in VAChT KDHOM mice,
suggesting that in vivo, the sympathetic nervous system needed
to be overactivated in VAChT KDHOM mice in order to maintain the basal HR at levels that were similar to those of the
WT. Second, the changes in ␤1-receptor expression and GRKs
observed for VAChT KDHOM mice are similar to those seen in
models of adrenergic overactivation (19, 39). Third, the effect
of sympathetic blockade on changes in HR responses were
significantly enhanced in VAChT KDHOM mice, suggesting an
important sympathetic component to maintenance of normal
values of heart rate in the mutant mice. It is therefore conceivable that dysautonomy caused by reduced cholinergic function in VAChT mutants favors an increased sympathetic tone
in these mice. The HR variability analysis conducted here
supports this conclusion.
An intriguing observation is the reduced heart rate found in
Langerdorff preparation-perfused hearts of mutant mice. This
finding agrees with the results of autonomic blockage in vivo
showing a reduced intrinsic heart rate in VAChT KDHOM
mice. It is likely that these results reflect reduced sinoatrial
node action potential firing in mutant mice. Future studies will
be needed to determine the ionic and molecular bases of these
changes.
Our findings contrast in part with the results obtained with
another model of cholinergic dysfunction, the M2-AChR
knockout mice (26). In spite of the similar in vivo HRs of the
VAChT KDHOM and M2-AChR knockout mice compared to
their respective controls, these two mouse strains presented
distinct degrees of cardiac dysfunction and remodeling. Since
most of the major cardiac changes observed in VAChT
KDHOM mice can be attributed to the reduced cholinergic
tone, it seems reasonable to have expected that the same array
of changes would be observed in the M2-AChR knockout mice.
One potential explanation for these phenotypic distinctions is
the degree of activation of ␤-adrenergic and muscarinic signaling. Whereas ␤-adrenergic responses were significantly altered
in VAChT mutants, this signaling pathway was preserved in
M2-AChR knockout mice (26). Moreover, VAChT mice presented exacerbated M2 responses, in contrast to M2-AChR
knockout mice, in which M2 responses were absent (26). There
is another consideration: the existence of other types of muscarinic receptors in the heart, albeit with lower levels of expression, has been reported (44, 49). Indeed, we could also
detect M1 and M3 muscarinic receptor messages in ventricular
cardiomyocytes, and their expression was elevated in VAChT
KDHOM mice. It is surprising that M2, M1, and M3 receptors
are all upregulated in ventricular myocytes from VAChT mu-
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